Program
Albumin-Bound Paclitaxel
Also written as “ABI-007”, “nab-paclitaxel” and “Nab-paclitaxel”.
Its studies are mostly in Pancreatic Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Melanoma, led by 11 companies.
Drug pageAlbumin-Bound Paclitaxel: every studyMany companies study it; this page follows only the 51 they lead. All 527 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 380 open or running | phase 4since May 28, 2014 | Sep 30, 2002 | none ahead |
| CSPC Pharmaceutical Groupits history only | 31 open or running | phase 3since Aug 15, 2017 | Aug 15, 2017 | none ahead |
| Theriva Biologics SLits history only | 20 open or running | phase 1since Jan 21, 2014 | Jan 21, 2014 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Mar 24, 2016 | Mar 24, 2016 | none ahead |
| Astellas Pharmaits history only | 10 open or running | phase 1since Nov 6, 2009 | Nov 6, 2009 | none ahead |
| EBG MedAustronits history only | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| Lee's Pharmaceuticalits history only | 10 open or running | phase 1since Sep 8, 2020 | Sep 8, 2020 | none ahead |
| Novartis | 10 open or running | phase 2since Jul 1, 2008 | Jul 1, 2008 | none ahead |
| NovoCureits history only | 10 open or running | phase 2since Feb 29, 2024 | Feb 29, 2024 | none ahead |
| Otsukaits history only | 10 open or running | phase 2since Apr 16, 2008 | Apr 16, 2008 | none ahead |
| SynerGene Therapeuticsits history only | 11 open or running | phase 2since Dec 18, 2014 | Dec 18, 2014 | Dec 2026phase 2 · NCT02340117 |
Also a collaborator on its studies: Gilead Sciences, Pfizer, Criterium and Shanghai Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2008First study: phase 2 study in Breast NeoplasmsFirst studyNCT00709761 · 60 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Novartis leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00709761Breast Neoplasms · United States | 2 | Completed | Jan 5, 2011 | 60 |
How it is read
Names in the registry
- “ABI-007”, 15 entries
- “nab-paclitaxel”, 13 entries
- “Nab-paclitaxel”, 12 entries
- “Nab-Paclitaxel”, 9 entries
- “nab-Paclitaxel”, 6 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 24 studies
- Breast Neoplasms, 14 studies
- Carcinoma, Non-Small-Cell Lung, 11 studies
- Triple Negative Breast Neoplasms, 4 studies
- Melanoma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.